MAPT and tauopathy: Transgenic models of TauP301L/S (Santacruz et al., 2005; Yoshiyama et al., 2007) and viral models of TauP301L (Cook et al., 2015; Wegmann et al., 2017) are useful tools to study the progression of tau pathology and investigate factors that could lead to the risk of developing any tauopathy, including AD.